Y-Intercept (HK)’s Neurogene NGNE Stock Holding History

Y-Intercept (HK)’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-680	Closed	-$14K	–	1172
2022 Q2	$14K	Buy	+680	New	+$16.6K	﹤0.01%	801

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Y-Intercept (HK)'s NGNE Position: Q3 2022 in Review

Y-Intercept (HK) sold out of Neurogene (NGNE) in Q3 2022, closing a stake of 680 shares — an estimated $14K sold.

Y-Intercept (HK) first reported a position in NGNE in Q2 2022 and held it in 1 quarter. The position peaked at $14K in Q2 2022. 52 funds tracked by Wall St. Rank hold NGNE as of Q3 2022.

Y-Intercept (HK) reported no remaining Neurogene position as of Q3 2022 after selling out during the quarter.
Y-Intercept (HK) sold 680 Neurogene shares in Q3 2022, an estimated $14K.
Y-Intercept (HK) first reported a position in Neurogene in Q2 2022 and held it in 1 quarter.
Y-Intercept (HK)'s Neurogene position peaked at $14K in Q2 2022.
52 funds tracked by Wall St. Rank held Neurogene as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.